Further studies reported the downregulation of DLC1 in other human cancers including lung, breast, renal, cutaneous melanomas, nasopharyngeal (NPC), esophageal, cervical, and prostate cancers [2–7]. Here, DLC1 is linked to prostate carcinoma.